NCT04070209View on ClinicalTrials.gov

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Metastatic Prostate CancerCastration-resistant Prostate Cancer
Interventions
DRUG

Darolutamide (BAY1841788)

Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.

RADIATION

SBRT

SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.

Trial Locations (10)

T2V 1P9

RECRUITING

Prostate Cancer Centre, Calgary

B3H 2Y9

RECRUITING

Centre of Applied Urology Research, Halifax

L8N 4A6

RECRUITING

St. Joseph's Healthcare Hamilton, Hamilton

J4V 2H3

RECRUITING

Service d'urologie et Centre de la prostate, Longueuil

H1T 2M4

RECRUITING

Hôpital Maisonneuve-Rosemont, Montreal

H2X 3E4

RECRUITING

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

H3T 1E2

RECRUITING

Sir Mortimer JGH, Montreal

G1R 2J6

RECRUITING

L'Hôtel-Dieu de Québec (CHUQ), Québec

J1H 5N4

RECRUITING

Hôpital Fleurimont (CHUS), Sherbrooke

G8Z 3R9

RECRUITING

Centre hospitalier affilié universitaire régional (CHAUR), Trois-Rivières

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER